Naturally occurring antibodies as next-generation immunotherapeutics for high-risk neuroblastoma
Klinische Pädiatrie · 01.05.2024 · 236 (03) · 201
DOI: 10.1055/s-0044-1786558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Pädiatrie, erschienen am 01.05.2024. Verfasst von I A Bley und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Neuroblastoma (NB), the most common extracranial solid tumour in children, presents a major clinical challenge for paediatric oncology. Despite advances in multimodal therapies, high-risk NB still has a poor prognosis and a high relapse rate, necessitating the development of novel therapeutic alternatives. In a recent study involving a cohort of 248 healthy individuals, we made an interesting discovery. Around 5% of the participants possessed naturally occurring antibodies (nAbs) within their serum that induced potent complement-mediated cytotoxicity in NB cells. We identified the antigen of these nAbs and confirmed their target specificity. Using the 10X barcode enabled antigen mapping (BEAM) technology, we identified antigen-specific B cell clonotypes of nAb+ donors, including their corresponding V(D)J sequences. These sequences are now used to produce recombinant antibodies, that will be characterized for their specificity and effectiveness against NB cells. Our findings hold great promise for the development of a new immunotherapeutic option. However, further research is needed to assess the antibody potency in preclinical and clinical settings. Publication History Article published online: 10 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Bley, I. A., Schattling, B., Rekowski, L., Sivanantham, S., Hunczek, A., Cornils, K., & Müller, I. (2024). Naturally occurring antibodies as next-generation immunotherapeutics for high-risk neuroblastoma. Klinische Pädiatrie, 236(03), 201. https://doi.org/10.1055/s-0044-1786558
Vancouver
Bley IA, Schattling B, Rekowski L, Sivanantham S, Hunczek A, Cornils K, et al. Naturally occurring antibodies as next-generation immunotherapeutics for high-risk neuroblastoma. Klinische Pädiatrie. 2024;236(03):201. doi:10.1055/s-0044-1786558
BibTeX
@article{Bley2024,
author = {Bley, I A and Schattling, B and Rekowski, L and Sivanantham, S and Hunczek, A and Cornils, K and Müller, I},
title = {Naturally occurring antibodies as next-generation immunotherapeutics for high-risk neuroblastoma},
journal = {Klinische Pädiatrie},
year = {2024},
volume = {236},
number = {03},
pages = {201},
doi = {10.1055/s-0044-1786558}
}
EUVIMED